Cellectis (NASDAQ:CLLS) Earns Sell Rating from Analysts at StockNews.com

StockNews.com assumed coverage on shares of Cellectis (NASDAQ:CLLS) in a report issued on Wednesday. The firm issued a sell rating on the biotechnology company’s stock.

Separately, Barclays reduced their price target on shares of Cellectis from $7.00 to $5.00 and set an “overweight” rating for the company in a report on Tuesday, November 5th.

Cellectis Price Performance

Cellectis stock opened at $1.93 on Wednesday. Cellectis has a 1 year low of $1.41 and a 1 year high of $3.38. The company has a current ratio of 1.78, a quick ratio of 1.78 and a debt-to-equity ratio of 0.48. The firm has a market capitalization of $107.28 million, a P/E ratio of -1.48 and a beta of 3.08. The business has a 50-day moving average of $1.85 and a 200-day moving average of $2.01.

Cellectis (NASDAQ:CLLS) last posted its earnings results on Monday, November 4th. The biotechnology company reported ($0.23) earnings per share for the quarter, missing the consensus estimate of ($0.20) by ($0.03). Cellectis had a negative return on equity of 74.55% and a negative net margin of 234.39%. The business had revenue of $18.05 million for the quarter, compared to the consensus estimate of $5.00 million. During the same quarter in the prior year, the firm posted ($0.31) earnings per share. On average, equities analysts anticipate that Cellectis will post -0.46 EPS for the current year.

Institutional Investors Weigh In On Cellectis

A number of institutional investors and hedge funds have recently made changes to their positions in CLLS. XTX Topco Ltd bought a new position in shares of Cellectis in the second quarter valued at about $29,000. First Affirmative Financial Network acquired a new stake in Cellectis during the third quarter worth approximately $45,000. Principal Financial Group Inc. increased its position in shares of Cellectis by 2.9% in the second quarter. Principal Financial Group Inc. now owns 437,000 shares of the biotechnology company’s stock worth $817,000 after purchasing an additional 12,467 shares during the period. Finally, Long Focus Capital Management LLC grew its stake in Cellectis by 2.9% during the second quarter. Long Focus Capital Management LLC now owns 4,617,293 shares of the biotechnology company’s stock worth $8,634,000 after buying an additional 130,000 shares in the last quarter. Institutional investors own 63.90% of the company’s stock.

Cellectis Company Profile

Cellectis SA, a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed or refractory for non-hodgkin lymphoma (NHL); and ALLO-715 for the treatment of multiple myeloma.